EGRX•globenewswire•
Eagle Pharmaceuticals Announces Divestiture of Barhemsys
Summary
WOODCLIFF LAKE, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the divestiture of the marketing authorization for Barhemsys (amisulpride) in the U.S. to LXO Group, Paris, France.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 14, 2026 by globenewswire